Organon’s Q2 2024 Revenues Grow 2% YOY, Sets Sights on Fertility Business Rebound in 2025
Organon (NYSE: OGN), a U.S.-based pharmaceutical company, has reported its financial results for the second...
Finanical Reports
Merck KGaA Posts 1.7% Q2 Growth Amid Varied Business Segment Performance
Merck KGaA (FRA: MRK) has reported its financial results for the second quarter of 2024,...
Zai Lab’s Q2 2024 Revenues Soar 47% YOY, Driven by Vyvgart and Zejula Sales
Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688), a leading biopharmaceutical company based in China, has...
Bayer AG’s Q2 2024 Global Group Sales Rise 3.1%, Driven by Pharmaceuticals and Consumer Healthcare
Bayer AG (OTCMKTS: BAYZF), a multinational pharmaceutical and life sciences company headquartered in Germany, has...
Eisai’s Q1 FY2024 Revenues Reflect Mixed Results with Leqembi Sales Doubling
Eisai Co., Ltd (TYO: 4523), a prominent Japanese pharmaceutical company, has released its financial results...
Daiichi Sankyo Reports 24.3% YOY Revenue Growth, Driven by Enhertu and Lixiana
Daiichi Sankyo (TYO: 4568), a leading pharmaceutical company in Japan, reported a significant year-on-year (YOY)...
GE Healthcare’s Q1 2024 Earnings Hit by China, Adjusts Annual Guidance
GE Healthcare Technologies Inc. (NASDAQ: GEHC), a leading player in the medical device and life...
Astellas Pharma Reports Robust Q1 FY2024 Results, Highlighting Growth in Core Therapies
Japan-based Astellas Pharma Inc. (TYO: 4503) has announced its financial results for the first quarter...
HutchMed Reports 2024 H1 Financials with Mixed Results Amid Strategic Focus on R&D and Commercial Efficiency
China-based HutchMed (NASDAQ: HCM) has released its financial report for the first half of 2024,...
GSK Reports Q2 2024 Earnings with 13% Growth, Vaccines Unit Sees Mixed Results
UK pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK, LON: GSK) has reported its financial results for...
Takeda Reports Q1 FY2024 Earnings with Growth in Key Therapies and New Launches
Japanese pharmaceutical company Takeda (TYO: 4502, NYSE: TAK) has announced its financial results for the...
Takeda Reports 3.7% YOY Revenue Growth in Q1 2023 Fiscal Year with Priority Products Driving Sales
Japan-based multinational Takeda (TYO: 4502) has released its financial report for the fiscal year 2023...
Pfizer Inc. Reports Q2 2024 Earnings with First Positive Growth Since Q4 2022 Peak
Pfizer Inc. (NYSE: PFE), a leading US pharmaceutical company, has announced its financial results for...
Merck’s Q2 2024 Earnings Miss Estimates as China Market Downturn Surprises
Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has reported its financial results for the...
WuXi AppTec’s H1 2024 Financials Reflect Decline Amid Biosecure Act Challenges
China-based Contract Development and Manufacturing Organization (CDMO) WuXi AppTec (HKG: 2359) has reported a subdued...
Philips Posts 2% Q2 2024 Sales Growth, Boosted by North American Demand
Royal Philips (NYSE: PHG), the Dutch electronics giant, reported its financial results for the second...
Bristol-Myers Squibb Q2 2024 Sales Boosted by Growth Portfolio, Offset by R&D Impairment
Bristol-Myers Squibb (BMS; NYSE: BMY) has announced its financial results for the second quarter of...
AbbVie’s Q2 2024 Results Show Resilience Amid Humira Biosimilar Challenges
AbbVie Inc. (NYSE: ABBV) has reported its financial results for the second quarter of 2024,...
Roche’s H1’24 Financials Show 5% Growth, Eye Care and Cancer Therapies Drive Sales
Roche (SWX: ROG, OTCMKTS: RHHBY, SWX: RO), the Swiss pharmaceutical and diagnostics giant, has reported...
AstraZeneca’s Q2 2024 Results Highlight Strong Growth Across Therapies, Excluding Vaccines
AstraZeneca (NASDAQ: AZN), a UK-based biopharmaceutical company, has reported its financial results for the second...